Calcitonin Salmon

Calcitonin Salmon is a polypeptide hormone. Commercial preparations of salmon calcitonin are prepared synthetically or using recombinant DNA methods. Salmon calcitonin is 40—50 times more potent than human Calcitonin and has a longer duration than human calcitonin. Salmon calcitonin differs from human calcitonin by 13 amino acid residues. Calcitonin Salmon prevents bone loss and fractures and increases bone density in patients with osteoporosis. In addition, Calcitonin Salmon reduces acute pain due to osteolytic fractures, vertebral crush fractures, and osteolytic bone metastasis. Clinically, Calcitonin Salmon is used in the treatment of Paget's disease of the bone, either alone or with other agents for the management of hypercalcemia, and as an adjunct to the treatment of postmenopausal osteoporosis.

Calcitonin Salmon’s innovator is Novartis, Avantis and is known world-wide by the brand names: Miacalcin® and Calcimar®.

Calcitonin Salmon is a hypocalcemic hormone whose effects are generally opposite those of parathyroid hormone (PTH). Calcitonin helps maintain calcium homeostasis. Secretion of Calcitonin Salmon is regulated by serum calcium; high serum calcium increases the release of Calcitonin Salmon. Catecholamines, glucagon, gastrin, or cholecystokinin may stimulate Calcitonin Salmon secretion. Calcitonin Salmon directly inhibits osteoclasts, binding to plasma-membrane receptors and increasing intracellular cyclic adenosine monophosphate (cAMP), as well as interfering with the membrane transport mechanisms of phosphate and calcium. Calcitonin Salmon lowers serum calcium concentrations by inhibiting bone resorption with subsequent decreases in elevated serum alkaline phosphatase concentrations and urinary hydroxyproline levels. The release of calcium and phosphate from bone is reduced, and the extent of collagen breakdown is decreased. Calcitonin Salmon antagonizes the actions of PTH, but concentrations of PTH do not increase significantly in response to Calcitonin Salmon therapy.
In addition, Calcitonin Salmon also has activity outside the bone and has antinociceptive activity that is independent of its activity on bone resorption.
 
Calcitonin Salmon appears in the following formation and dosage:
Injection 200 IU/ml (6,000 IU = 1 mg, source EP 2005)
Nasal spray 200 IU/Actuation

General data on Calcitonin Salmon Active Pharmaceutical Ingredient

CAS Registry: 47931-85-1
ATC: H05BA01
Molecular Formula: C145H240N44O48S2
Molecular Weight: 3431.9
Pharmacopoeias: In Chin. and Eur.

Ph. Eur. 5.5: Calcitonin Salmon is a white or almost white powder. It is obtained by chemical synthesis or by a method based on recombinant DNA (rDNA) technology. Calcitonin Salmon Freely soluble in water.

TAPI's Calcitonin Salmon Pharmaceutical Ingredient

TAPI's Calcitonin Salmon Active Pharmaceutical Ingredient is produced in Assia Chemical Industries Limited - Teva Tech site in Beer Sheva, Israel.

Over the last 15 years TAPI has developed the expertise in developing and commercialization of peptide Active pharmaceutical ingredients, such as Calcitonin Salmon. With numerous worldwide approvals, we are continuously driven by the goal of helping our customers achieve success-and ultimately approval for their peptide APIs. We offer grams to hundred kilograms production capabilities, comprehensive technology platform including solid phase, solution phase, and hybrid approach, combined with a well established scientific experience, enabling the implementation of efficient process aimed for high quality product. We offer Custom Synthesis and Manufacturing services on peptide Active pharmaceutical ingredients.

TAPI provide full service on Calcitonin Salmon and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Calcitonin Salmon. Contact us today for further inquiries and samples availability information for TAPI's Calcitonin Salmon.

Other peptides available on TAPI's portfolio are: Bivalirudin, Desmopressin Acetate, Eptifibatide, Exenatide, Tariparatide Acetate, Leuprolide/ Leuprorelin Acetate and Octreotide Acetate.Contact us today for sample availability and any other information on these products.

2008 Available DMF: EU CTD.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients